so much potential !
is this for real. 
ProShares UltraShort Materials
SMN
Ishares Trust U.S. Pharmaceuticals Etf
IHE
United States Natural Gas
UNG
4
SPDR S&P Retail ETF
XRT
5
The Health Care Select Sector SPDR® Fund
XLV
US Stock MarketDetailed Quotes
Jupiter Neurosciences (JUNS)
- 0.2250
- -0.0068-2.93%
Close Jun 10 16:00 ET
- 0.2436
- +0.0186+8.27%
Pre 04:00 ET
9.77MMarket Cap-0.87P/E (TTM)
0.2300High0.2141Low2.00MVolume0.2240Open0.2318Prev Close445.07KTurnover8.44%Turnover RatioLossP/E (Static)43.42MShares3.330052wk High-3.52P/B5.34MFloat Cap0.172152wk Low--Dividend TTM23.74MShs Float19.5100Historical High--Div Yield TTM6.86%Range %0.1721Historical Low0.2222Avg Price1Lot Size
JUNS Stock Chart
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
JUNS Orderflow
Unit: --
JUNS Orderflow Trend
IntradayDayWeekMonth
No Data
Jupiter Neurosciences (JUNS) News
Jupiter Neurosciences Promotes Silva to COO and President
Bitcoin Steadies Above $60,000 While Derivatives Send an Unambiguous Warning
Jupiter Neurosciences, Inc. Initiates Patient Enrollment for Phase 2a RESET Trial of JOTROL in Parkinson's Disease
Express News | Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a Reset Trial in Parkinson’s Disease
D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection With Its ~$2 Million Registered Direct Offering
Jupiter Neurosciences, Inc. Secures $2 Million in Direct Offering to Support Parkinson's Program and Strengthen Balance Sheet
Jupiter Neurosciences (JUNS) Stock Forum
$Jupiter Neurosciences (JUNS.US)$ Buy before announcement tomorrow
2
$Jupiter Neurosciences (JUNS.US)$
$JUNS May 20th, 2026 secured a term sheet valued at over $100 million to exclusively license the U.S. rights to ALA-002, a next-generation MDMA therapeutic, from PharmAla Biotech. The agreement bolsters Jupiter's central nervous system (CNS) development pipeline. Immediately filed for $2 Million offering, the offering closed.
On April 18, 2026, President Donald Trump signed an executive order which he stated would "dramatically accelerate access to new medical r...
$JUNS May 20th, 2026 secured a term sheet valued at over $100 million to exclusively license the U.S. rights to ALA-002, a next-generation MDMA therapeutic, from PharmAla Biotech. The agreement bolsters Jupiter's central nervous system (CNS) development pipeline. Immediately filed for $2 Million offering, the offering closed.
On April 18, 2026, President Donald Trump signed an executive order which he stated would "dramatically accelerate access to new medical r...
+1
1
1
$Jupiter Neurosciences (JUNS.US)$ I like $JUNS, biotechs been ripping, this one a good one, secured $100 Million term sheet, it sank because of offering, offering over, now thry cannot do more offerings, filings say, for 30 days after 4th offering they shall not do another for 30 days....They just had a filing today and have a history of running.up their stock, compliance until.the end of August, by which they can do another 180 day extension....looks like we are clean for 30 days, could run past...
1
2
$Jupiter Neurosciences (JUNS.US)$ Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease
2
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)
76258540 : What announcements are scheduled for tomorrow?
Reefer King OP 76258540 :